Targeting transgene expression to specific hematopoietic cell lineages could contribute to the safety of retroviral vectors in gene therapeutic applications. Chronic granulomatous disease (CGD), a defect of phagocytic cells, can be managed by gene therapy, using retroviral vectors with targeted expression to myeloid cells. In this context, we analyzed the myelospecificity of the human miR223 promoter, which is known to be strongly upregulated during myeloid differentiation, to drive myeloid-restricted expression of p47 phox and gp91 phox in mouse models of CGD and in primary patient-derived cells. The miR223 promoter restricted the expression of p47 phox , gp91 phox , and green fluorescent protein (GFP) within self-inactivating (SIN) gamma-and lentiviral vectors to granulocytes and macrophages, with only marginal expression in lymphocytes or hematopoietic stem and progenitor cells. Furthermore, gene transfer into primary CD34+ cells derived from a p47 phox patient followed by ex vivo differentiation to neutrophils resulted in restoration of Escherichia coli killing activity by miR223 promoter-mediated p47 phox expression. These results indicate that the miR223 promoter as an internal promoter within SIN gene therapy vectors is able to efficiently correct the CGD phenotype with negligible activity in hematopoietic progenitors, thereby limiting the risk of insertional oncogenesis and development of clonal dominance.
Introduction
C hronic granulomatous disease (CGD) comprises a group of immunodeficiencies characterized by malfunctioning of the phagocytic nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, resulting in defective reactive oxygen species (ROS)-dependent killing of microbes and consequently leading to recurrent severe bacterial and fungal infections (Seger, 2008) . About 67% of CGD cases result from mutations within the X-linked CYBB gene encoding the gp91 phox subunit of NADPH oxidase (X-CGD), whereas 16% result from malfunction of the p47 phox subunit (van den Berg et al., 2009) .
The first clinically successful gene therapy (GT) trial for primary immunodeficiency was reported in 2000 (CavazzanaCalvo et al., 2000) . Since then, the list of indications for which GT treatment led to permanent or temporary benefit for treated patients has been continuously growing (Aiuti et al., 2002; Mavilio et al., 2006; Morgan et al., 2006; Ott et al., 2006; Kaplitt et al., 2007; Bainbridge et al., 2008; Cartier et al., 2009; Boztug et al., 2010; Cavazzana-Calvo et al., 2010; Porter et al., 2011) .
For CGD, the first clinically successful X-CGD GT trial with proven restoration of ROS production and resolution of treatment refractory Aspergillus infections was initiated in 2004 in Frankfurt and Zü rich. In this study, a gammaretroviral long terminal repeat (LTR)-driven vector containing a strong spleen focus-forming virus (SFFV) promoter/ enhancer was used to express gp91 phox . However, vectormediated transactivation of the EVI1 proto-oncogene in progenitor cells resulted in clonal dominance progressing to genetic instability and myelodysplastic syndrome (MDS) (Stein et al., 2010) . These severe side effects revealed the need of vector redesign to avoid vector-mediated genotoxic effects. This could be achieved by using vectors with self-inactivating (SIN) configuration and cell-type-specific internal enhancer/promoters, thereby restricting transgene expression to the deficient cell compartment (i.e., to granulocytes, monocytes, and macrophages in CGD) and limiting the risk of proto-oncogene transactivation to cells with limited life span (reviewed in Toscano et al., 2011 ). Herewith, we tested the human miR223 regulatory region, which is highly active only in myeloid cells, in the context of SIN gamma-and lentiviral vectors (Fukao et al., 2007) for its expression specificity, stability over time, and its ability to restore NADPH oxidase function and mediate bacterial killing.
Materials and Methods

Antibodies and reagents
Anti-human CD14-FITC, anti-human CD206-FITC (clone 19.2), anti-Ly6G-FITC (clone 1A8), anti-Gr1-PE (clone RB6-8C5), anti-B220-FITC or APC-Cy7 (clone RA3-6B2), anti-CD3-PE (clone 17A2), anti-CD11b-PE (clone M1/70), antiScaI-PE (clone E13-161.7), mouse Fc-block (clone 2.462), and Cytofix/Cytoperm Kit were from Beckton Dickinson (Basel, Switzerland), as was anti-p47 phox (clone 1)-APC labeled by Beckton Dickinson services. Anti-CD11b-PerCP/Cy5.5, APC or PE-Cy7 (clone M1/70), anti-F4/80-PerCP/Cy5.5 (clone BM8) and anti-CD117-FITC or APC (clone 2B8), CD45.1-PE or PE-Cy7 (clone A20), CD45.2-PercP-Cy5.5 (clone 104), and ScaI-PE-Cy7 (clone D7) were from eBiosciences (Vienna, Austria). Anti-CD11C-PerCP (clone N418) came from Biolegend (Uithoorn, The Netherlands). Anti-DLNGFR-APC, human and mouse Lineage Cell Depletion Kits, CD14 microbeads, and Gr1-VioBlue (clone RB6-8C5) were from Miltenyi Biotec GmbH (Bergisch Gladbach, Germany). For intracellular p47 phox staining combined with surface staining, cells were blocked for 10 min at 4°C, incubated with surface staining antibodies for 1 hr, and washed twice followed by intracellular staining using Cytofix/Cytoperm according to manufacturer's description.
Animals
p47
phox-/-(B6[Cg]-Ncf1 m1J /J) and gp91 phox-/-(B6.129S-Cybb tm1Din /J) mouse husbandry and animal experiments were carried out in compliance with the local animal protection law.
Vector construction
The 5¢ regulatory region of the human miRNA223 promoter (782 bp, chrX:65,234,612-65,235,394 GRCh37/hg19 assembly) was amplified from PLB985 gDNA using the following primers: forward, 5¢-CATATGACTTGTACAGCT TCACAGGGCTCC (NdeI linker); reverse, 5¢-GGATCCCTGT CAGTGGAGTGGTGC (BamHI linker). This element was cloned into lentiviral vectors via the NdeI-BamH1 sites to replace the MRP8 promoter in the MRP8-gp91-wPRE (MgpW) vector or the corresponding GFP-containing MEW vector. Gammaretroviral constructs were derived from the pSER11M8DN91s vector (M. Grez) by exchanging the transgene against a synthetic human p47 phox reading frame (Geneart, Regensburg, Germany) and by exchanging the internal promoter against promoter candidates (Supplementary Fig. S1 ; Supplementary Material available online at www.liebertonline.com/hgtb). The gammaretroviral vector encoding SFFV:DLNGFR-2A-p47 phox was already described (Wohlgensinger et al., 2010) . In this construct, the SFFV promoter was exchanged against the miR223 promoter. Lentiviral vectors encoding miR223 p47 phox were derived from the pCCL.CHIM.GP91 phox .WPRE (Santilli et al., 2011) by exchanging the promoter and the transgene.
Virus production
Virus supernatants were produced in 293T cells upon cotransfection with pMD2.VSV.G with CMVDR8.91 for lentiviral vectors or pUMVS plus the gene transfer vector for gammaretroviral vectors ( Supplementary Fig. S1 ), using TransIT-293 transfection reagent (Mirus Bio LLC, Madison, WI) or calcium phosphate-mediated transfection. Culture supernatants were collected after 24 and 48 hr, sterilefiltered, concentrated in Ultracal-100K Centrifugal Filters (Millipore, Zug, Switzerland) or by ultracentrifugation (2 hr at 50,000 g at 4°C), and stored at -80°C.
Transduction and ex vivo granulocytic differentiation
Murine lineage-negative (Lin-) bone marrow (BM) cells were isolated from femur and tibias of 6-12-week-old mice using the Miltenyi lineage cell depletion kit (Miltenyi Biotec GmbH). The cells were prestimulated for 24 hr in StemSpan SFEM (StemCell Technologies, Grenoble, France) supplemented with mouse stem cell factor (mSCF) (10 ng/ml), mouse thrombopoietin (mTPO) (20 ng/ml), mouse insulinlike growth factor 2 (mIGF-2) (20 ng/ml), and human fibroblast growth factor 1 (hFGF1) (10 ng/ml) (all from Peprotech, Hamburg, Germany) at 0.5 · 10 6 to 1 · 10 6 cells per milliliter. Transduction was carried out at 20-50 multiplicity of infections (MOIs) in the presence of protamine sulfate (6 lg/ml) for 24 hr in 24-well plates. The cells were cultivated for another 24 h before transplantation. For granulocytic differentiation in vitro, the cells were incubated in RetroNectin (Takara Bio Europe/SAS, Saint-Germain-en-Laye, France) plates in differentiation medium 1 (RPMI) supplemented with 20% fetal calf serum (FCS) and 25 ng/ml mouse granulocyte colony-stimulating factor (mG-CSF) for 3 days up to 2 weeks.
After informed consent, human Lin-cells were isolated from BM aspirates of a p47 phox CGD patient, using the Lineage Cell Depletion Kit (Miltenyi Biotec GmbH). Lin-BM cells were expanded for 3 days on 24-well plates coated with RetroNectin in X-Vivo 10, penicillin/streptomycin, 2 mM Lglutamine, 50 ng/ml human interleukin-3 (hIL-3), 150 ng/ml human stem cell factor (hSCF), 150 ng/ml human FMS-like tyrosine kinase 3 (flt3) ligand (hFlt3L), 50 ng/ml human thrombopoietin (hTPO), and 2% FCS (or 1% bovine serum albumin). For retroviral transduction, cells were harvested and centrifuged onto virus preloaded RetroNectin plates.
For ex vivo differentiation, cells were harvested again and seeded on RPMI (10% FCS, penicillin/streptomycin, 50 ng/ml hSCF, 10 ng/ml human granulocyte colony-stimulating factor (hG-CSF), 10 ng/ml hFLT3L) at day 1. At day 10, cells were shifted to differentiation medium 2 (differentiation medium 1 without SCF) and incubated for another 10 days, followed by 152 BRENDEL ET AL.
FACS sorting using a BD FACSAria Flow Cytometer (Beckton Dickinson, Basel, Switzerland).
Animal GT p47 phox-/-and gp91 phox-/-mice received lethal (9.5 Gy or a split dose of 2 · 5.5 Gy) irradiation. About 1 · 10 6 to 2 · 10 6 gene-modified Lin-BM cells were injected intravenously. Animals were sacrificed after 7-23 weeks, and blood, spleen, BM, and peritoneal macrophages were analyzed for transgene expression.
Escherichia coli killing assay
The assay was conducted as described recently (Ott et al., 2006) with minor modification. Granulocytes were coincubated with opsonized E. coli at a ratio of 1:10 for 30 min at 32°C. Essentially, neutrophils were incubated with the E. coli strain ML-35. This particular strain lacks the membrane transport protein lactose permease and constitutively expresses b-galactosidase (b-Gal). Engulfment of E. coli ML-35 by neutrophils is followed by perforation of the bacterial cell wall and accessibility to b-Gal, which is subsequently inactivated by ROS (Hamers et al., 1984) . Briefly, 2 · 10 9 E. coli/ ml were opsonized with 20% (v/v) Octaplas (Octapharma AG, Lachen, Switzerland) for 5 min at 37°C. Opsonized E. coli (final concentration, 0.9 · 10 8 /ml) were added to granulocytes (0.9 · 10 7 /ml). At defined time points, granulocytes were lyzed with 0.05% saponin (Calbiochem, Darmstadt, Germany) and the samples were incubated with 1 mM orthonitrophenyl-bD-galactopyranoside (Sigma-Aldrich, Seelze, Germany) at 37°C for 30 min. b-Gal activity was followed by standard procedures at 420 nm.
Human monocytes/macrophage culture
After informed consent, human monocytes were isolated using CD14 microbeads. Cryostorage in CryoSto CS10 (StemCell Technologies) resulted in 30% survival upon thawing. Monocytes were cultured, transduced at a high MOI, and differentiated to macrophages in RPMI, 10% Octaplas, 2 mM L-Gln, 10 mM HEPES, 2 mM sodium pyruvate, and M-CSF 100 ng/ml.
Nitroblue tetrazolium test
Macrophages were incubated in 1 mg/ml nitroblue tetrazolium (NBT; Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) in phosphate buffered saline (PBS) containing 200 ng/ml phorbol myristate acetate (PMA) plus 0.5 nmol/ml N-FormylMet-Leu-Phe (fMLP) (both from Sigma-Aldrich Chemie GmbH) for 1 hr at 37°C and fixed thereafter in PBS and 2% formaldehyde (Merck [Schweiz] AG, Zug, Switzerland). Photographs were taken on a Leica DM-IL microscope with a DFC-480 camera (Leica Microsystems [Schweiz] AG, Heerbrugg, Switzerland).
Dihydrorhodamine 123 assay
About 10 6 granulocytes in 1 ml of Hanks Balanced Salt Solution (HBSS) with Ca/Mg, 0.5% human albumin, 1000 U catalase, 7.5 mM glucose, and antibodies were stimulated with 200 ng PMA and incubated for 5 min at 37°C. Then, dihydrorhodamine 123 (DHR) was added to a final concentration of 0.435 lM, incubated for further 15 min at 37°C, kept on ice for 30 min, and analyzed using FACS Calibur (Beckton Dickinson, Basel, Switzerland) or FACS Canto II (Beckton Dickinson, Heidelberg, Germany).
Results
The miR223 promoter induces transgene expression upon granulocytic differentiation in vitro
To identify a myeloid-restricted promoter adequate for the gene therapy of CGD, we analyzed the promoter activity of a 782-bp DNA fragment derived from the human miR223 promoter within SIN gamma-and lentiviral vector constructs, as earlier reports have indicated strong and specific upregulation of miR223 gene expression during myeloid differentiation (Fukao et al., 2007; Landgraf et al., 2007; Johnnidis et al., 2008) . We tested the miR223 promoter in conjunction with the gp91 phox and the p47 phox subunits of the phagocytic NADPH oxidase as well as with a DLNGFR-2A-p47 phox fusion construct (Wohlgensinger et al., 2010 ) (Supplementary Fig. S1 ).
Initially, we transduced murine Lin-BM cells obtained from p47
phox-/-animals with SIN gammaretroviral vectors harboring p47 phox under control of the miR223 promoter, and compared this with the specificity of other promoters derived from myeloid-restricted genes such as cFES (Heydemann et al., 2000) and MRP8 , or synthetic promoters like the p40/48 (a 250-nt chimeric promoter consisting of two PU.1 transcription factor binding sites from the p40 and one PU1 site from the p47 promoter), or the Sp107 (He et al., 2006) promoters. We used the SFFV promoter as a benchmark for high expression levels in myeloid cells (Supplementary Fig. S1 ). p47 phox expression was analyzed by FACS upon intracellular p47 phox staining 2 days after transduction in ScaI+ cells as well as in ex vivo differentiated Ly6G+ granulocytes generated thereof (Supplementary Fig. S2A ). The mean fluorescence intensity (MFI) ratio of p47 phox expression in differentiated versus undifferentiated cells was used to estimate the induction of transgene expression upon myeloid differentiation. In this screen, the miR223 promoter showed the strongest induction of p47 phox expression among the promoters tested ( Supplementary Fig.  S2C ). In addition, differentiated cells were analyzed for ROS production in a DHR oxidation assay. We observed a consistent increase in DHR+ granulocytes from cFes, p40/48, and the miR223-corrected cells, but only the miR223-corrected population showed a statistically significant increase of DHR+ cells compared with the mock control (Supplementary Fig. S2B and D) . Next, we transduced the human myelomonocytic cell line X-CGD PLB985 with a lentiviral SIN vector encoding gp91 phox under control of the miR223 promoter (223gpW). Transductions at MOIs of 2 and 0.2 resulted in moderate gp91 phox expression levels in 51% and 10% of the cells, respectively. Upon differentiation, the percentage of gp91 phox -expressing cells increased to 70% and 19%, respectively, in parallel to a significant increase in expression levels (Fig. 1A) . Restoration of ROS production could be confirmed in 57% of the cells transduced at an MOI of 2, with DHR MFIs comparable to those of differentiated wild-type PLB-985 cells (Fig. 1B) .
We generated single clones of PLB-985 cells transduced with a lentiviral vector encoding GFP under control of the miR223 promoter in order to quantify gene expression without variations resulting from antibody staining. The analysis revealed a good correlation between vector copy number (VCN) and transgene expression particularly in differentiated cells (R 2 = 0.94), whereas a reduced correlation was evident in undifferentiated cells (R 2 = 0.69) (Fig. 1C) . In 53 monoclonal populations, the mean fold induction of GFP expression upon granulocytic differentiation was 3.5 -0.88 ( Fig. 1D ) with a coefficient of variation of only 25.7%. Moreover, GFP signals in these clones remained stable during the total observation period of 4 months (Fig. 1E) .
The induction of transgene expression and reconstitution of NADPH oxidase activity could also be confirmed in granulocytes obtained upon ex vivo differentiation of transduced murine Lin-gp91 phox-/-BM cells. Lentiviral transduction with the vector harboring gp91 phox under SFFV promoter control (SgpW) resulted in similar expression of gp91 phox in hematopoietic progenitors (cKit + ScaI+ ) and granulocytes (CD11b+ Gr1+ ) ( Fig. 2A) with good reconstitution of ROS production in differentiated CD11b+ Gr1+ cells (Fig. 2B) . On the other hand, the miR223 promoter 
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(223gpW) mediated weak gp91 phox expression in a small fraction (6%) of the hematopoietic progenitors (cKit+ ScaI+ CD11b-Gr1-), whereas 62% of the CD11b+ Gr1+ cells showed significant amounts of gp91 phox expression, confirming induction of miR223 promoter activity upon granulocytic differentiation. As in PLB-985 cell-derived granulocytes (Fig. 1B) , miR223-driven gp91 phox expression also mediated high levels of ROS production in granulocytes derived from transduced primary murine Lin-cells with ROS levels similar to those observed in granulocytes derived from wild-type (C57Bl6) or SgpW-transduced X-CGD cells (Fig. 2B) .
Collectively, these results strongly indicate an induction of miR223 promoter activity upon granulocytic differentiation regardless of transgene identity or the vector system utilized.
The miR223 promoter drives myelo-specific transgene expression in CGD mouse models in vivo
To characterize the miR223 promoter activity in vivo, we monitored transgene expression patterns in gp91 -/-and p47 -/-mouse models of CGD. After lentiviral transduction of X-CGD Lin-BM cells with 223gpW and reinfusion into lethally irradiated recipient mice, gp91 phox expression was analyzed in donor cells up to 23 weeks after transplantation ( Fig. 3A and B; Supplementary Fig. S3 ). Expression in BM LSK (Lin-ScaI+ cKit+ ) cells and lymphoid cells (CD3+ or B220+ ) was almost undetectable, while increasing amounts of gp91 phox were detected during differentiation from progenitor LSK cells (Lin-ScaI-cKit+ ) to monocytes (CD11b + Gr1-) and to mature granulocytes (CD11b Gr1+ ). Gp91 phox expression in granulocytes led to the reconstitution of NADPH oxidase activity and ROS production as analyzed by the DHR assay. The percentages of DHR+ granulocytes correlated with the percentages of gp91 phox expression in individual animals, and DHR MFIs indicate the production of significant amounts of ROS at moderate VCNs between 0.7 and 1.5 (Fig. 3B) .
In the p47 -/-animal model, an miR223 p47 phox gammaretroviral vector ( Supplementary Fig. S1 ) was used to transduce syngeneic Lin-BM cells, and cell populations were analyzed for p47 phox expression by intracellular staining 7 weeks after reinfusion (Fig. 3C) . Very low expression of p47 phox was observed in BM cKit+ ScaI+ or splenic T and B cells (data not shown), and expression levels in monocytes remained under the detection limit. Expression levels in granulocytes were below 11% at an average of 4%, indicating one copy per cell (Fehse et al., 2004) . Although MFIs of p47 phox + granulocyte signals were moderate, ROS production was restored in all animals (Fig. 3D) . The percentages of DHR+ granulocytes closely correlated with the percentages of p47 phox FACS+ granulocytes (R 2 = 0.9872). No adverse events regarding animal health, organ size, and appearance were observed during these studies. Furthermore, there was no decline of expression over time, which might indicate the absence of epigenetic silencing.
The miR223 promoter is active in p47 phox -deficient macrophages
As NADPH oxidase function is required in granulocytes and in macrophages, we tested transgene expression in peritoneal macrophages of NADPH oxidase-deficient animals. Lethally irradiated p47 phox-/-mice were reconstituted with Lin-cells transduced with a gammaretroviral vector encoding the DLNGFR-2A-p47 phox fusion construct under miR223 control, allowing for indirect p47 phox detection by DLNGFR surface staining (Wohlgensinger et al., 2010) . Significant DLNGFR expression was observed in F4/80+ peritoneal macrophages in all treated animals, indicating miR223 promoter activity in macrophages (Fig. 4A) , while DLNGFR detection signals in splenic T and B cells and blood dendritic cells were in the range of background staining (Fig.  4B) . Next, we analyzed the miR223 promoter activity in primary human macrophages obtained from blood monocytes of a p47 phox -deficient CGD patient. Monocytes were transduced with lentiviral vectors encoding p47 phox under control of the SFFV or the miR223 promoter and differentiated to macrophages for 7 days, resulting in high levels of transduction for both vectors (Fig. 4C) . ROS production in primary macrophages was confirmed in an NBT reduction assay upon PMA/fMLP stimulation (Fig. 4D) , clearly indicating miR223 promoter activity in this cell type.
The miR223 promoter-controlled p47 phox expression restores E. coli killing activity in primary human granulocytes
To analyze whether miR223 promoter-driven p47 phox expression restores granulocyte anti-microbial activity, we transduced Lin-BM cells from a p47 phox -deficient CGD patient with the gammaretroviral vector encoding the DLNGFR-2A-p47 phox fusion construct under miR223 or SFFV transcriptional control followed by granulocytic differentiation ex vivo. DLNGFR surface staining circumvents intracellular staining for p47 phox for functional analyses and allows for the enrichment of gene-modified cells. In differentiated myeloid cells, gene marking rates of 7%-10% were observed (Fig. 5A) . Stimulation of these cells with either PMA or opsonized E. coli resulted in DHR oxidation exclusively in DLNGFR + cells, indicating restoration of ROS production in a p47
phox -dependent manner (Fig. 5B) . DLNGFR surface marking of neutrophils, together with CD11b marking of differentiated granulocytes, was used to FACS-sort mocktransduced p47 phox + (DLNGFR+ ) and p47 phox -(DLNGFR-) granulocytes (all CD11b+ ) derived from cRetro-SIN miR223-DLNGFR-2A-p47 phox and cRetro-SIN SFFV-DLNGFR-2A-p47 phox -transduced cells. Sorted cell populations were then analyzed in an E. coli killing assay (Ott et al., 2006) . In this assay, an increase in optical density at 420 nm indicates effective bacterial killing. Both DLNGFR+ populations showed effective restoration of E. coli killing activity, whereas the CD11b+ /DLNGFR-populations derived from the same cultures were unable to kill E. coli (Fig. 5C) . Thus, antimicrobial function was restored in neutrophils expressing p47 phox under control of the miR223 (as well as SFFV) promoter. These data reinforce the potential utility of the miR223 promoter for high and myeloid-restricted transgene expression.
Discussion
Transactivation of proliferation-promoting genes as the primary cause of clonal dominance in gene therapy studies can potentially be avoided by the use of SIN vectors driving transgene expression from an internal tissue-specific promoter rather than from strong constitutively active promoters such as the viral LTR (Zychlinski et al., 2008; Modlich et al., 2009; Montini et al., 2009) . Another potential risk arises from transcriptional read-through, that is, the extension of viral transcripts through the virus-genome border into the genomic sequence or splicing of vector transcripts into cellular exons. Both features have contributed to leukemia formation in animal models and clinical studies (Cesana et al., 2012) . For CGD, a myelo-specific promoter driving transgene expression preferentially in phagocytes could be an option to   FIG. 4 . miR223 promoter activity in macrophages. Lin-BM cells from p47 phox-/-mice were gammaretrovirally transduced (miR223-DLNGFR-2A-p47 phox ) and reinfused into lethally irradiated p47 phox-/-mice. FACS analysis of (A) DLNGFR expression in peritoneal macrophages and (B) T, B, and dendritic cells after 8 weeks revealed preferential expression in peritoneal macrophages. (C) Frozen blood monocytes from a p47 phox CGD patient were taken into culture overnight and lentivirally (miR223-p47 phox ) transduced. The cells were kept in culture for 7 days, followed by FACS analysis of p47 phox expression in macrophages (CD206+ CD14+ ). (D) Functional reconstitution of ROS production was analyzed in macrophages by nitroblue tetrazolium assay. ROS, reactive oxygen species.
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limit transgene expression to short-lived cells, thereby theoretically limiting the risks associated with enhancer-or readthrough-mediated activation of proto-oncogenes (Kustikova et al., 2009; Toscano et al., 2011) . The study was motivated by the results obtained during the long-term follow-up of CGD patients treated by gene therapy revealing transactivation of EVI1 as primary cause of clonal dominance with development of MDS, and promoter silencing leading to treatment failure (Stein et al., 2010) . In our study, we evaluated the properties of a DNA fragment derived from the human miR223 regulatory region as an internal promoter within SIN retroviral vectors for the gene therapy of CGD, as the hsa-miR223 gene was reported to be transcribed nearly exclusively within the hematopoietic compartment (Landgraf et al., 2007) in a highly myeloidspecific manner (Fukao et al., 2007; Johnnidis et al., 2008) .
In the gp91 phox -deficient mouse model, miR223-driven gp91 phox expression resulted in up to 43% gp91 phox + granulocytes, but the same resulted in only 0.3%-2.2% gp91 phox + early stem and progenitor cells (LSK cells) and in a maximum of 1.8% positive T and B cells, as assessed by intracellular staining despite mean VCNs of 0.7-1.5 (Fig. 3A) . The lack of gp91 phox expression in immature primitive progenitors and B and T cells could be attributed to a detection bias, as gp91 phox is not stable in cells lacking p22 phox , the second component of the cytochrome b558 complex. However, p22 phox is ubiquitously expressed (Chambers et al., 2007) and gp91 phox can be easily detected in LSK cells transduced with SgpW, a lentiviral vector containing the SFFV enhancer/ promoter element driving gp91 phox expression ( Fig. 2A ) . Similarly, in the p47 phox model, miR223-mediated p47 phox expression was weak in BM cKit+ /ScaI+ cells and undetectable in T and B cells, while neutrophils were up to 10.3% p47 phox + . Although the analyses of both models were performed at different time points, hematopoiesis after 7 or more weeks is mainly maintained by mid-and long-term repopulating multipotent progenitors (Dykstra et al., 2007; Gerrits et al., 2010) . Therefore, lineagespecific expression is unlikely to originate from the transduction of lineage-restricted progenitors but rather truly reflects the specificity of the miR223 promoter element. The expression distribution observed in our experiments resembles the expression pattern of the miR223 gene in mice ( Johnnidis et al., 2008) and humans (Allantaz et al., 2012) . Moreover, our in vitro experiments show that the miR223 promoter can direct gp91 phox expression in a VCN-dependent manner and generates levels of superoxide equivalent to those observed in differentiated wild-type human myeloid cell lines and in vitro differentiated murine neutrophils (Figs. 1 and 2) .
Myeloid-restricted expression of the miR223 gene has been attributed to the action of a complex regulatory loop including the coordinate binding of CEBP and PU.1 to a region upstream of the major pri-miR223 transcription start site (MTSS) and to the binding of C/EBPa and NFI-A to a nonconserved responsive element 2710 bp downstream of the MTSS, which corresponds to an intron of the pri-miR223 transcript (Fukao et al., 2007) . Although the detailed interplay of these two regulatory regions in mediating tissue specificity has not been clarified, evidence exists that the intronic regulatory region contributes to miR223 expression specificity (Fazi et al., 2007) . The DNA fragment used in our studies comprises the MTSS and includes the CEBP and PU.1 Stimulation with opsonized E. coli (lower panels) resulted in ROS production in 1.3%, 32.1%, and 35.5% of the double-positive cells. (C) Transduced CD11b+ cells were separated by FACS as indicated by the DLNGFR gates shown in (A) (purity: SFFV, 87%; miR223, 93%). The isolated populations were analyzed for their E. coli killing capacity in a standard killing assay using the E. coli strain ML35. An increase in optical density at 420 nm indicates bacterial killing activity. sites but lacks the binding sites for C/EBPa and NFI-A. Despite this, a myeloid-restricted expression pattern was observed in vitro and in vivo.
A recent study characterized a myelo-specific chimeric promoter generated by the fusion of cathepsin G and c-Fes minimal 5¢-flanking regions driving gp91 phox expression within a lentiviral SIN vector (Santilli et al., 2011) . In comparison to this vector, the 223gpW exhibits even lower leakiness in lymphocytes and more importantly in LSK cells. One possible explanation for this is the lack of SP1-binding sites in the miR223 DNA fragment used in this study, which are present in the chimeric promoter and which may account for the low levels of gene expression seen in primitive progenitors transduced with SIN vectors containing the chimeric promoter (Santilli et al., 2011) .
Alternatively, miRNA target sequences can also be used to restrict transgene expression to the desired target population (Brown et al., 2007) . Best example of this is the use of the miR126 target sequences to detarget expression of an otherwise toxic gene product (galactocerebrosidase) from HSCs in the context of gene therapy for globoid cell leukodystrophy (Gentner et al., 2010) .
Although targeting gene expression to myeloid cells in the context of CGD is a reasonable approach, there is no experimental evidence for a toxic effect of gp91 phox expression in hematopoietic primitive progenitor cells (Grez et al., 2011) . Thus, the relevant issue for CGD vectors is the absolute reconstitution of superoxide levels, as the analysis of 227 CGD patients revealed a close correlation between superoxide production levels and long-term survival (Kuhns et al., 2010) .
Unfortunately, a restricted tissue-specific transgene expression frequently yields weak expression levels. The question is whether, despite the high specificity, miR223-mediated expression levels are sufficient to correct the CGD phenotype.
In our hands, FACS-sorted p47 phox + neutrophils derived from the BM cells of transduced Lin-p47 phox -deficient patients clearly demonstrated E. coli killing activity ex vivo for both SFFV-and miR223-containing vectors compared with the fraction of untransduced neutrophils, indicating that the level of miR223-mediated p47 phox expression in neutrophils is sufficient to restore the physiological antimicrobial function of these cells (Fig. 5) .
ROS production seems to possess a triggering role for antimicrobial defense mechanisms, and it is a prerequisite for NET formation and extracellular killing (Bianchi et al., 2009) . Already, very low amounts of granulocytic ROS production result in significant changes in membrane potential, K+ efflux, and bacterial killing (Rada et al., 2004) . This indicates that low levels of gp91 phox or p47 phox expression in CGD phagocytes could result in significant physiological improvement in the clinical status of treated patients. In mice, already 4%-8% of wild-type granulocytes or 11%-21% genemodified neutrophils were sufficient to protect X-CGD mice against respiratory challenge with Aspergillus fumigatus conidia, although a significant higher number of genecorrected neutrophils was required to improve host defense of X-CGD animals against Staphylococcus aureus and Burkholderia cepacia (Dinauer et al., 2001; Urban et al., 2009; Bianchi et al., 2011) . We expect our tissue-specific miR223 vectors to show an improved safety profile compared to vectors with ubiquitously active promoters, as our highly myelo-specific expression pattern strongly limits the promoter activity in stem and progenitor cells and thus may prevent the occurrence of side effects while restoring the physiological antimicrobial function of gene-corrected neutrophils.
